Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 31.6 49.9 63.4% View Chart
P/BV x 4.5 13.4 33.7% View Chart
Dividend Yield % 0.8 0.5 164.0%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8491,639 51.8%   
Low Rs5571,115 50.0%   
Sales per share (Unadj.) Rs573.8186.3 308.0%  
Earnings per share (Unadj.) Rs176.051.0 345.4%  
Cash flow per share (Unadj.) Rs198.257.3 345.8%  
Dividends per share (Unadj.) Rs6.2516.00 39.1%  
Dividend yield (eoy) %0.91.2 76.5%  
Book value per share (Unadj.) Rs842.7261.8 321.9%  
Shares outstanding (eoy) m36.50265.47 13.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.27.4 16.6%   
Avg P/E ratio x4.027.0 14.8%  
P/CF ratio (eoy) x3.524.0 14.8%  
Price / Book Value ratio x0.85.3 15.9%  
Dividend payout %3.631.4 11.3%   
Avg Mkt Cap Rs m25,660365,592 7.0%   
No. of employees `0005.011.8 41.8%   
Total wages/salary Rs m3,5595,423 65.6%   
Avg. sales/employee Rs Th4,225.34,175.1 101.2%   
Avg. wages/employee Rs Th718.0457.7 156.9%   
Avg. net profit/employee Rs Th1,295.91,141.8 113.5%   
INCOME DATA
Net Sales Rs m20,94549,463 42.3%  
Other income Rs m1,3021,556 83.7%   
Total revenues Rs m22,24751,019 43.6%   
Gross profit Rs m7,94818,718 42.5%  
Depreciation Rs m8101,689 48.0%   
Interest Rs m19335 551.4%   
Profit before tax Rs m8,24718,551 44.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8235,023 36.3%   
Profit after tax Rs m6,42413,527 47.5%  
Gross profit margin %37.937.8 100.3%  
Effective tax rate %22.127.1 81.6%   
Net profit margin %30.727.3 112.1%  
BALANCE SHEET DATA
Current assets Rs m23,47246,501 50.5%   
Current liabilities Rs m7,2878,468 86.1%   
Net working cap to sales %77.376.9 100.5%  
Current ratio x3.25.5 58.7%  
Inventory Days Days92131 70.5%  
Debtors Days Days8886 102.8%  
Net fixed assets Rs m18,64825,797 72.3%   
Share capital Rs m365531 68.8%   
"Free" reserves Rs m34,52568,962 50.1%   
Net worth Rs m30,76069,493 44.3%   
Long term debt Rs m00-   
Total assets Rs m43,03180,383 53.5%  
Interest coverage x43.7531.0 8.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 79.1%   
Return on assets %15.416.9 91.1%  
Return on equity %20.919.5 107.3%  
Return on capital %27.426.7 102.6%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m11,53641,238 28.0%   
Fx outflow Rs m2,93912,405 23.7%   
Net fx Rs m8,59728,833 29.8%   
CASH FLOW
From Operations Rs m6,6889,543 70.1%  
From Investments Rs m-6,122-6,854 89.3%  
From Financial Activity Rs m-509-2,459 20.7%  
Net Cashflow Rs m66230 28.7%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  JUBILANT PHARMOVA   ELDER PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS